Two Sigma Securities, LLC V Tv Therapeutics Inc. Transaction History

Two Sigma Securities, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.42 - $0.75 $12,789 - $22,837	30,450 New	30,450 $14,000
Q4 2022 Feb 14, 2023	BUY	$0.66 - $40.8 $3,740 - $231,213	5,667 Added 17.5%	38,052 $25,000
Q3 2022 Nov 14, 2022	BUY	$0.65 - $38.8 $9,483 - $566,092	14,590 Added 81.99%	32,385 $31,000
Q2 2022 Aug 15, 2022	SELL	$0.39 - $0.84 $297 - $641	-764 Reduced 4.12%	17,795 $13,000
Q1 2022 May 16, 2022	SELL	$0.51 - $1.0 $12,519 - $24,549	-24,549 Reduced 56.95%	18,559 $13,000
Q4 2021 Feb 14, 2022	BUY	$0.95 - $1.69 $24,719 - $43,975	26,021 Added 152.29%	43,108 $43,000
Q3 2021 Nov 15, 2021	BUY	$1.53 - $2.22 $26,143 - $37,933	17,087 New	17,087 $26,000
Q3 2019 Nov 14, 2019	SELL	$1.26 - $1.77 $33,707 - $47,351	-26,752 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.29 - $1.83 $34,510 - $48,956	26,752 New	26,752 $38,000
Q4 2018 Feb 14, 2019	SELL	$0.78 - $3.74 $13,256 - $63,561	-16,995 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$0.7 - $1.58 $11,896 - $26,852	16,995 New	16,995 $13,000

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.38B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.